Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aronex Pharma (ARNX) -- Ignore unavailable to you. Want to Upgrade?

To: Vendit™ who wrote (207)	1/16/1999 8:41:00 PM
From: Sam Lee	Read Replies (1) \| Respond to of 320

I don't post much on Yahoo. All the filth is unnecessary. I have not traded Aronex b/c I do not want to lose my long term gain rate if we do get a run. Also, I have a friend who has been around folks who have a great regard of atragen and its potential. Once the NDA is approved, which is a given, then additional uses can be added on as they are proven. You don't have to go through the whole process again. Also, if it is on the market then it can be prescribed for off label use. Nyotran is about ready for the NDA and it will also be approved. Trouble is that it will be a long time before Aronex gets any revenue from sales. And the stock may not move seriously until that happens. I am just sitting and waiting and sometimes thinking of all the interest I could have drawn on the money.